On course to publish our scientific research and findings.

We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.

Date Type Description Link
Apr 2022 Poster

ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML, AACR Annual Meeting 2022

Dec 2021 Poster

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML via Suppression of Oxidative Phosphorylation and Purine Biosynthesis, 63rd ASH Annual Meeting, December 2021

Aug 2020 Journal Papers

Zhang, et al. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone. J Pharmacol Exp Ther. 2020 Aug;374(2):308-318.

Jan 2020 Journal Papers

Quintela-Fandino, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020 Jan 1;26(1):35-45.

Aug 2019 Journal Papers

Zhang, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79(16):4072-4085.

Jan 2019 Poster

A randomized phase 0 trial of the mitocondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC), ASCO Annual Meeting, June 2019

Jan 2019 Journal Papers

Zhang, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019;142:187-207

Aug 2018 Poster

Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: a phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC), ASCO Annual Meeting, June 2018

Jan 2017 Journal Papers

Diamond, et al. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 Oct;35(5):627-633.

Aug 2016 Journal Papers

Jeyaraju, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016 Aug 2;7(31):49777-49785.

Aug 2016 Journal Papers

Manevich, et al. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 Aug;358(2):199-208.

Jun 2016 Journal Papers

Navarro, et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Rep. 2016 Jun 21;15(12):2705-18.

Apr 2015 Journal Papers

Bendell, et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 1;121(7):1056-63.

Apr 2015 Poster

ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor. AACR Annual Meeting, Apr 2015

Jan 2015 Journal Papers

Lim, et al. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I). Am J Cancer Res. 2015 Jan 15;5(2):689-701.

Aug 2011 Journal Papers

Alvero, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011 Aug;10(8):1385-93.

Jul 2009 Journal Papers

Alvero, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009 Jul 15;115(14):3204-16